Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease

Next Previous
X
Search
Trial Profile

A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Azathioprine; Mercaptopurine; Methotrexate
  • Indications Crohn's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TAILORIX

    • Most Recent Events

    • 09 May 2023 Results assessing performance of a Bayesian PK tool in forecasting exposure and disease control in IBD patients starting Infliximab from patients form TAILORIX trial & PRECISION trial, presented at the Digestive Disease Week 2023.
    • 23 May 2021 Results(n=116) of population PK model analysis evaluating the value of combined monitoring of sIFX and EHI in a single serum sample of patients with CD for guiding IFX dose optimization presented at the Digestive Disease Week 2021
    • 01 Jan 2021 Results of post-hoc analysis published in the American Journal of Gastroenterology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top